Login
Did The New York Times turn one board chairman’s objections into a misleading narrative of institutional opposition to U.S. Health Secretary Robert F. Kennedy’s vaccine injury research initiative?
New information provided to TrialSite News by multiple Washington sources raises troubling questions about the newspaper’s Oct. 16 report, which portrayed the National Institutes of Health (NIH) Clinical Center Research Hospital Board as unanimously rebuking Kennedy over the proposed clinic.
Reporter Sheryl Gay Stolberg reported a unanimous board rebuke. However, sources familiar with the proceedings challenge the implication that the board unanimously opposed the research initiative.
They allege that chairman Jack Leslie acted without full board participation and that subsequent discussions involving broader participation demonstrated support for investigating possible vaccine injuries.
All of this suggests that the Times crossed an important journalistic line: transforming a limited institutional dispute into a broader narrative of scientific opposition that the underlying record does not support.
What did the NIH board actually oppose?
The distinction is fundamental. A board’s unanimous endorsement of criticism directed at Kennedy is not necessarily a unanimous rejection of research into possible vaccine injuries.
According to sources speaking with TrialSite News on condition of anonymity, not all board members participated in the initial proceedings. When broader discussions reportedly addressed the actual research initiative, members expressed unanimous support for proceeding with appropriate scientific oversight.
These accounts remain subject to documentary confirmation. Meeting minutes, attendance records, the precise language of any motion and subsequent deliberations should establish exactly what happened.
Stolberg reported that an NIH spokesperson confirmed the board’s position. But that confirmation leaves a critical question unanswered: Was the board objecting to Kennedy’s characterization of the clinic, its proposed governance or the scientific investigation itself?
Those are three very different matters.
If the board supported investigating vaccine injuries while expressing concerns about Kennedy’s presentation or implementation, portraying the episode primarily as an institutional rebuke risks leaving readers with a materially misleading impression. Was that the aim?
The Times certainly needs to clarify what was actually voted upon, who participated and whether its reporting accurately reflected the board’s position.
The potential conflict of interest the Times should have examined
Investigative journalist Paul D. Thacker raised another significant issue on Oct. 19: Leslie’s continuing professional connections to Weber Shandwick, a major public relations firm with pharmaceutical and vaccine-industry clients.
Although the Times identified Leslie as a former chairman of Weber Shandwick, Thacker questioned whether that description adequately disclosed his ongoing associations.
Such relationships do not prove improper influence. Leslie may have legitimate scientific, ethical or governance objections to Kennedy’s initiative.
But transparency matters.
When an individual with professional ties to a firm serving pharmaceutical interests publicly challenges a government initiative investigating potential vaccine injuries, readers deserve enough information to evaluate those relationships for themselves.
The issue is not whether Leslie should have been quoted. It is whether the newspaper subjected his institutional authority and potential conflicts to the same scrutiny it applied to Kennedy.
A newspaper cannot credibly demand transparency from government officials while overlooking relevant questions about the interests and authority of the sources it relies upon.
NIH leadership has publicly supported scientific investigation
An important development complicates any suggestion that NIH leadership broadly opposes investigating possible vaccine injuries.
In an official statement concerning the new NIH Vaccinology and Immunology Center, NIH Director Jay Bhattacharya and National Institute of Allergy and Infectious Diseases Acting Director John H. Powers III declared:
“People who report serious health problems, including those that occur after vaccination or long-term symptoms after infections, deserve to be heard, taken seriously, and evaluated with the best tools science can offer.”
This is an important institutional statement.
It affirms that people reporting serious health problems following vaccination deserve scientific attention rather than dismissal.
NIH Clinical Center CEO Jonathan Green also reportedly indicated that the proposed research would undergo established scientific and ethical review.
Neither statement establishes how individual board members voted. Nevertheless, both provide essential context for understanding the distinction between legitimate concerns about research oversight and opposition to the underlying scientific inquiry.
Investigating possible vaccine injuries is not inherently political. It is a legitimate scientific responsibility. And there is certainly a moral and ethical responsibility to patients.
Did political framing overtake accurate reporting?
TrialSite News is leaning toward a troubling conclusion: The Times may have crossed the line between reporting a legitimate institutional disagreement and constructing a misleading narrative of unanimous scientific opposition.
The newspaper had every right to report Leslie’s objections. It had every right to investigate Kennedy’s proposal, question its scientific design and examine whether the initiative would meet established research standards.
But those obligations extend to accurately representing the board’s actions and distinguishing documented institutional decisions from the interpretations of individual participants.
If the broader board supported the research while raising concerns about Kennedy’s approach, that distinction should have been central to the story — not lost beneath the headline.
The possibility of incomplete sourcing also deserves examination. Did the Times independently verify the scope of the vote? Did it establish who participated? Did it seek the views of members who may have disagreed with Leslie’s characterization? And did it adequately disclose relevant professional relationships?
These are not peripheral questions. They determine whether readers received an accurate account of an important public-health dispute.
TrialSite News calls for the release of relevant NIH board records and a clear explanation from Leslie, NIH officials and the Times regarding what actually occurred.
If the records contradict the impression conveyed by the newspaper’s coverage, a prominent clarification or correction would be warranted.
The larger problem: When vaccine hesitancy mitigation threatens scientific independence
For years, TrialSite News has examined how an intense institutional focus on reducing vaccine hesitancy can, at times, conflict with the equally important obligation to investigate potential vaccine-related harm.
Vaccination has delivered substantial public-health benefits and TrialSite has been on the record on the benefits of vaccination. But acknowledging those benefits must never require minimizing credible reports of adverse events or discouraging independent investigation.
Scientific confidence is not built by avoiding difficult questions. It is earned through rigorous research, transparency, replication and an openness to findings that may challenge prevailing assumptions.
Patients reporting serious health problems following vaccination deserve access to credible investigations. Their experiences should neither be accepted as proof of causation without evidence nor dismissed simply because the subject is politically sensitive.
The same principle applies to journalism.
When reporting treats vaccine injury research primarily as a political controversy surrounding Kennedy, rather than a scientific question deserving independent scrutiny, it risks reinforcing the very institutional pressures journalism should investigate.
The purpose of science is to discover what is true — not to protect public-health messaging from inconvenient findings. The purpose of journalism is to establish what happened — not to reinforce a preferred political narrative.
A test of journalistic accountability
The Times has the influence to shape how policymakers, scientists, physicians and millions of Americans understand this controversy. That influence carries an obligation to get the institutional record right.
If the newspaper accurately characterized the board’s position, the records should demonstrate it.
If it did not, the public deserves a correction.
But the larger issue extends beyond one reporter, one board chairman, or one health secretary.
Scientific independence must protect the investigation of possible vaccine injuries — not become a rationale for discouraging it.
Too often, TrialSite News has documented concerns that an almost singular focus on mitigating vaccine hesitancy can overshadow the pursuit of good science. That imbalance deserves examination regardless of who occupies the White House or leads the U.S. Department of Health and Human Services.
And the standards of accountability cannot change depending on whether the subject is Kennedy or one of his critics.
The Times must answer a straightforward question: Did it report the NIH board’s actual position, or did it present a narrower dispute in a way that led readers to believe the scientific establishment had unanimously rejected vaccine injury research?
That question deserves an answer supported by documents, not competing narratives.
Ultimately, this controversy should not be about protecting Kennedy, Leslie, NIH leadership or the reputation of the Times. It should be about protecting the integrity of scientific inquiry and the public’s right to accurate information.
Patients deserve answers. Science deserves independence. Journalism demands accountability. And when powerful institutions get the story wrong, their obligation is not to defend the narrative — it is to correct the record.
Originally published by Trial Site News.
